RecruitingNCT06283316
Systemic Treatments for Alopecia Areata Registry
Sponsor
Erasmus Medical Center
Enrollment
10,000 participants
Start Date
Jan 17, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.
Eligibility
Min Age: 16 Years
Inclusion Criteria3
- Diagnosed with alopecia areata;
- Starting/using a systemic treatment for alopecia areata;
- Informed consent for registry participation obtained from patient and/or caretaker.
Exclusion Criteria2
- Not sufficiently capable of understanding the Dutch language;
- Not willing to participate.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06283316
Related Trials
Deciphering the Genetic Architecture of Autoimmune Diseases
NCT069481102 locations
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT0753300630 locations
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
NCT075862671 location
Natural History of Type 1 Interferonopathies: Insights From a European Cohort
NCT0704077432 locations
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240269 locations